Chinese Journal of Tissue Engineering Research ›› 2012, Vol. 16 ›› Issue (40): 7438-7443.doi: 10.3969/j.issn.2095-4344.2012.40.006

Previous Articles     Next Articles

Clinical application of rituximab in antibody mediated rejection after renal transplantation

Liu Tian-lai, Liu Yong-guang, Li Min, Guo Ying, Li Liu-yang, Zhao Ming   

  1. Department of Organ Transplantation Center, Zhujiang Hospital of Southern Medical University, Guangzhou 510282, Guangdong Province, China
  • Received:2012-06-04 Revised:2012-07-12 Online:2012-09-30 Published:2012-09-30
  • Contact: Zhao Ming, Doctor, Doctoral supervisor, Chief physician, Professor, Department of Organ Transplantation Center, Zhujiang Hospital of Southern Medical University, Guangzhou 510282, Guangdong Province, China zhaoming02@hotmail.com
  • About author:Liu Tian-lai★, Studying for master’s degree, Physician, Department of Organ Transplantation Center, Zhujiang Hospital of Southern Medical University, Guangzhou 510282, Guangdong Province, China liutianlai0429@126.com

PDF

726

Abstract:

BACKGROUND: Foreign literatures show that the application of rituximab in antibody mediated rejection after renal transplantation has significant efficacy and good safety. But there still lacks of report and research of these in China.
OBJECTIVE: To investigate the efficacy and safety of rituximab in the treatment of antibody mediated rejection after renal transplantation.
METHODS: Eighteen patients who diagnosed with antibody mediated rejection after renal transplantation were divided into two groups, and all the patients in two groups received immunosuppressive therapy. Patients in the experimental group (n=8) received single dose rituximab treatment; patients in the control group (n=10) were treated without single dose rituximab treatment.
RESULTS AND CONCLUSION: After treated for 6 and 12 months, the creatinine level in the experimental group was lower than that in the control group (P < 0.05). After 6-12 months follow-up, in experimental group, one patient with cytomegaoviyns, one patient with urinary tract infection, no life-threatening infection during the follow-up period, and the patient/graft survival rate was 100%. It indicates that rituximab for the treatment of antibody mediated rejection after renal transplantation has significant efficacy and good safety.

CLC Number: